Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.

Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Abstract Text:

    masahiko igarashiMasahiko Igarashi,yumi jimbuYumi Jimbu,minako kimuraMinako Kimura,akihiko hirataAkihiko Hirata,hiroshi yamaguchiHiroshi Yamaguchi,makoto tominagaMakoto Tominaga,masahiko igarashiMasahiko Igarashi,yumi jimbuYumi Jimbu,minako kimuraMinako Kimura,akihiko hirataAkihiko Hirata,hiroshi yamaguchiHiroshi Yamaguchi,makoto tominagaMakoto Tominaga,

    The aim of this study was to evaluate the anti-atherogenic efficacy of pioglitazone, a thiazolidinedione derivative, on the change in atherogenic outcomes by comparing responder and non-responder groups in type 2 diabetic patients. Twenty-three patients with poor diabetic control were treated with 15 mg of pioglitazone for 12 months. The levels of fasting plasma glucose (FPG), HbA1c, triglycerides (TG), total cholesterol (T-Cho), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) were measured monthly, and those of remnant-like particle-cholesterol (RLP-C) and lipoprotein (a) [Lp (a)] were measured every 3 months. In Month 6, the patients were divided into two groups according to the decrease in HbA1c level: the responder group showed a decrease of > or =1%; the non-responder group, a decrease of <1%. In the responder group, the levels of FPG and HbA1c decreased significantly after Month 3. The values of the body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index, LDL-C, and RLP-C were significantly higher in the responder group than in the non-responder group. Although the levels of T-Cho and HDL-C were unchanged in both groups, those of TG and RLP-C were drastically reduced in the responder group. Interestingly, the relative change in Lp (a) was significantly decreased in both groups. These results strongly suggest that pioglitazone is beneficial for type 2 diabetic patients with high levels of BMI, HOMA-IR, LDL-C, and RLP-C, as it helps to prevent the progression of atherosclerosis, including coronary heart diseases.

    Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Publishing Authors By Initials

    m igarashiM Igarashi,y jimbuY Jimbu,m kimuraM Kimura,a hirataA Hirata,h yamaguchiH Yamaguchi,m tominagaM Tominaga,m igarashiM Igarashi,y jimbuY Jimbu,m kimuraM Kimura,a hirataA Hirata,h yamaguchiH Yamaguchi,m tominagaM Tominaga,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Diabetes research and clinical practice

    VOLUME: 77

    Page Numbers: 389-98

    Journal Abbreviation: Diabetes Res. Clin. Pract.

    ISSN: 0168-8227

    DAY: 2

    MONTH: 02

    YEAR: 2007

    Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8508335

    Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.

    AFFILIATION: Department of Laboratory Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan. migarasi@med.id.yamagata-u.ac.jp

    Country: Ireland

    Ireland Research PublicationIreland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Diabetes Res Clin Pract

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News